Skip to main content
. 2024 Dec 30;22:178. doi: 10.1186/s12961-024-01274-9

Table 1.

Participant summary

Phases of study Specialized field Number of participants
Phase 1 Health and pharmaceutical policy-maker 10
Active in pharmaceutical industry, anti-cancer medicine 5
Phase 2 Health and pharmaceutical policy-maker 3
Having relevant previous policy and management experience 2
Active in pharmaceutical industry, anti-cancer medicine 2
Faculty member in field of health and pharmaceutical policy 2